The Menopause Market is driven by the rising awareness of women’s health, increasing demand for personalized treatments, and advancements in hormone therapy.

 

DelveInsight’s “Menopause Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Menopause, historical and forecasted epidemiology as well as the Menopause market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Menopause Market with DelveInsight’s In-Depth Report @ Menopause Market Size

 

Key Takeaways from the Menopause Market Report

• In November 2024:- Astellas Pharma Inc.- A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause.
• In November 2024:- Pfizer- The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer. Participants will have a screening period for up to 28 days. If deemed fit, they will receive study treatment for 14 days, and then will have a follow-up visit about 28 days after their last dose.
• The Menopause market is projected to witness consistent growth throughout the forecast period (2024–2034) at a compound annual growth rate (CAGR) of 1.2%. The total number of women in menopause were estimated to be around 100 million in 2023 in the 7MM.
• The number of women in menopause in the US in 2023 accounted for nearly 41% of total number of cases for Menopause in the 7MM. During the study period, these numbers are expected to rise at a significant CAGR.
• The stage-specific distribution of women in menopause typically includes three stages: Peri-menopause (40–65 years), Post-menopause (40–65 years), Premature Menopause (below 40 years). DelveInsight estimated that among the different stages of menopause, women in post-menopause stage (40–65 years) were highest in number (73,395 thousand cases) in 2023 in the 7MM.
• For the age-specific analysis, number of cases of menopause were distributed across various age groups, such as
• Japan accounted for 18% of the number of women in menopause in the 7MM in 2023, with 18,096 thousand cases.
• In 2023, 64,650 thousand women in menopause experienced hot flashes, making it the most common symptom during this stage of life. While, 54,250 thousand women had night sweats in the 7MM.
• In the EU4 and the UK, around 40% of all menopause cases in the US exhibited moderate-to-severe vasomotor symptoms in 2023.
• The leading Menopause Companies such as Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer|Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others.
• Promising Menopause Therapies such as NOE-115, Cellular Matrix / A-CP-HA Kit, Elinzanetant, Fezolinetant, PF-07220060, Denosumab, Alpelisib, and others.

 

Stay ahead in the Menopause Therapeutics Market with DelveInsight’s Strategic Report @ Menopause Market Outlook

 

Menopause Epidemiology in the 7MM

• Total Number of Women in Menopause
• Stage-specific Distribution of Women in Menopause
• Age-specific Distribution of Women in Menopause
• Number of Women in Menopause with Vasomotor Symptoms
• Number of Women in Menopause with Moderate-to-severe Vasomotor Symptoms

 

Download the report to understand which factors are driving Menopause epidemiology trends @ Menopause Prevalence

 

Menopause Marketed Drugs

 

• DUAVEE/DUAVIVE (bazedoxifene acetate/conjugated estrogens): Pfizer/Ligand Pharmaceuticals

DUAVEE (bazedoxifene acetate/conjugated estrogens) was the first and only therapy to pair conjugated estrogens (CE) with an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator (SERM). DUAVEE, approved by the FDA in 2013 and the EMA in 2014, provides the benefits of estrogen while minimizing the potential risks by including bazedoxifene, which helps protect against endometrial hyperplasia. With its convenient once-daily dosing, DUAVEE offers a convenient and reliable solution for managing menopausal symptoms, allowing women to regain control of their lives and embrace this new phase with confidence and comfort.

 

• VEOZAH (fezolinetant): Astellas Pharma

VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for treating moderate-to-severe VMS due to menopause. VEOZAH offers a safe and non-hormonal option, addressing the challenges and discomfort associated with menopause and providing optimal support for women experiencing menopause. In May 2023, VEOZAH was approved by the US FDA for treatment of vasomotor symptoms due to menopause.

 

Menopause Emerging Drugs

• NOE-115: Noema Pharma AG

NOE-115 is a broad-spectrum monoamine modulator in mid-stage clinical development as a non-hormonal treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause, administered orally once daily. NOE-115 has been safe and well-tolerated to date in studies in healthy volunteers. NOE-115 has the potential to benefit VMS during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms.

 

• FP-101: Fervent Pharmaceuticals

FP-101 is a non-hormonal/non-herbal/non-antidepressant product for the treatment of vasomotor symptoms associated with menopause and hot flashes. Fervent’s FP-101 was shown to be potentially effective in treating vasomotor symptoms.

 

Get In-Depth Knowledge on Menopause Market Trends and Forecasts with DelveInsight @ Menopause Treatment Market

 

Menopause Market Outlook

Hot flushes are the most bothersome and prevalent menopause-related symptom, affecting up to 85% of menopausal women with different severity, frequency, and duration. Hot flashes associated with menopause are treated using two main categories of drugs: hormonal therapies and non-hormonal therapies. The Menopause Market is expected to experience positive growth with the approval of potential drugs like NOE-115, FP-101, and others.

 

Scope of the Menopause Market Report

• Coverage- 7MM
• Menopause Companies- Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer|Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others.
• Menopause Therapies- NOE-115, Cellular Matrix / A-CP-HA Kit, Elinzanetant, Fezolinetant, PF-07220060, Denosumab, Alpelisib, and others.
• Menopause Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Menopause Unmet Needs, KOL’s views, Analyst’s views, Menopause Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Menopause Market Report @ Menopause Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Country-wise Menopause Market Overview

4 Menopause Market Overview by Class

5 Methodology of Menopause Epidemiology and Market

6 Executive Summary of Menopause

7 Key Events

8 Disease Background and Overview

9 Epidemiology and Patient Population

10 Menopause Patient Journey

11 Menopause Marketed Therapies

12 Menopause Emerging Therapies

13 Menopause: Market Analysis

14 Key Opinion Leaders’ Views

15 SWOT Analysis

16 Menopause Unmet Needs

17 Reimbursement and Market Access

18 Appendix

19 Bibliography

20 Report Methodology

21 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/